World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
49606
World Ranking
5724
National Ranking
3077

Nyla A. Heerema publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nyla A. Heerema sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 572 publications — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nyla A. Heerema D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nyla A. Heerema sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 109 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nyla A. Heerema is affiliated with The Ohio State University in the United States. Their research primarily focuses on the field of Medicine, with significant contributions to hematology and related subfields. Heerema's work spans several specialized areas including hematology, public health, genetics, pediatrics, and molecular biology.

Heerema has published extensively on topics related to leukemia and other blood cancers. Their main topics of research cover:

  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Childhood Cancer Survivors' Quality of Life
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders

Frequent collaborators of Heerema include:

  • Andrew J. Carroll
  • Meenakshi Devidas
  • Stephen P. Hunger
  • Mignon L. Loh
  • Elizabeth A. Raetz

Heerema's publications have appeared predominantly in established venues known for hematology and oncology research. Their most frequent publication venues are:

  • Blood
  • Journal of Clinical Oncology
  • Leukemia
  • Cancer Genetics
  • Blood Advances

Notable recent papers include:

  • "The genomic landscape of pediatric acute lymphoblastic leukemia," 2022, Nature Genetics
  • "Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia," 2020, Journal of Clinical Oncology
  • "Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial," 2020, Nature Medicine
  • "Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study," 2020, Clinical Cancer Research
  • "Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia," 2020, Journal of Clinical Oncology

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

    K. G. Roberts;Y. Li;D. Payne-Turner;R. C. Harvey

  • Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

    M Smith;D Arthur;B Camitta;A J Carroll

  • The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia

    Yu Liu;John Easton;Ying Shao;Jamie Maciaszek

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • Cytogenetics in acute leukemia

    Krzysztof Mrózek;Nyla A Heerema;Clara D Bloomfield

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

    Kirk R. Schultz;W. Paul Bowman;Alexander Aledo;William B. Slayton

  • Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

    Sarah E. M. Herman;Amber L. Gordon;Amy J. Wagner;Nyla A. Heerema

  • The genomic landscape of hypodiploid acute lymphoblastic leukemia

    Linda Holmfeldt;Lei Wei;Ernesto Diaz-Flores;Michael Walsh

  • Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

    Charles G Mullighan;J Racquel Collins-Underwood;Letha A A Phillips;Michael G Loudin

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

    Kami J. Maddocks;Amy S. Ruppert;Gerard Lozanski;Nyla A. Heerema

  • Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

    Gerard Lozanski;Nyla A. Heerema;Ian W. Flinn;Lisa Smith

  • Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)

    Kirk R. Schultz;D. Jeanette Pullen;Harland N. Sather;Jonathan J. Shuster

  • Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

    William Blum;Ramiro Garzon;Rebecca B. Klisovic;Sebastian Schwind

  • Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

    Krzysztof Mrózek;Guido Marcucci;Deedra Nicolet;Kati S. Maharry

  • Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

    Brian V. Balgobind;Susana C. Raimondi;Susana C. Raimondi;Jochen Harbott;Martin Zimmermann

  • Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

    K. R. Schultz;A. Carroll;N. A. Heerema;W. P. Bowman

  • Rearrangement of CRLF2 in B-Progenitor and Down Syndrome Associated Acute Lymphoblastic Leukemia.

    Charles G. Mullighan;J. Racquel Collins-Underwood;Letha A Phillips;Michael G. Loudin

Frequent Co-Authors

John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Stephen P. Hunger
Stephen P. Hunger University of Pennsylvania
Meenakshi Devidas
Meenakshi Devidas St. Jude Children's Research Hospital
Andrew J. Carroll
Andrew J. Carroll University of Alabama at Birmingham
William L. Carroll
William L. Carroll New York University
Mignon L. Loh
Mignon L. Loh University of California, San Francisco
Naomi J. Winick
Naomi J. Winick The University of Texas Southwestern Medical Center
Elizabeth A. Raetz
Elizabeth A. Raetz New York University
Michael J. Borowitz
Michael J. Borowitz Johns Hopkins University
Brent L. Wood
Brent L. Wood University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and complementary degrees can expand your options in the healthcare field beyond studying Medicine in the USA. For those interested in wellness and preventive care, there are numerous online nutrition degree programs available that can lead to rewarding careers as dietitians or health coaches.

If you're focused on the administrative side of healthcare, pursuing a Master of Healthcare Administration from a CAHME-accredited MHA program can open doors to leadership roles in hospitals and health organizations.

Registered nurses seeking to advance their education without attending in-person clinicals can consider an RN to BSN online no clinicals program for greater career flexibility.

Advanced nursing professionals may be interested in the shortest post master's DNP program options, which can quickly propel them into top clinical or administrative roles.

Each of these pathways provides unique benefits and specialization opportunities, making them excellent alternatives or complements to a traditional medical degree.

Best Scientists Citing Nyla A. Heerema

Trending Scientists

Recently Published Articles